# De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC

> **NCT06692725** · — · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 380 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06692725
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06692725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06692725, "De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06692725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*